Your browser doesn't support javascript.
loading
The impact of 2 weeks wait referral on survival of head and neck cancer patients.
Rovira, Aleix; Russell, Beth; Trivedi, Priyanka; Ojo, Onaiho; Oakley, Richard; Byrne, Edie; Daryanani, Avisha; Van Hemelrijck, Mieke; Simo, Ricard.
Afiliação
  • Rovira A; Division of Surgical Oncology, Head and Neck Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK. aleix.rovira@gstt.nhs.uk.
  • Russell B; Cancer Epidemiology, King's College London, London, UK.
  • Trivedi P; King's College London, London, UK.
  • Ojo O; King's College London, London, UK.
  • Oakley R; Division of Surgical Oncology, Head and Neck Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Byrne E; Division of Surgical Oncology, Head and Neck Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Daryanani A; Division of Surgical Oncology, Head and Neck Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Van Hemelrijck M; King's College London, London, UK.
  • Simo R; Translational Oncology and Urology Research, King's College London, London, UK.
Eur Arch Otorhinolaryngol ; 280(12): 5557-5564, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37526700
ABSTRACT

PURPOSE:

This study aims to evaluate the association between 2 weeks wait referral and survival in the head and neck cancer.

METHODS:

Retrospective cohort study of consecutively discussed new head and neck cancer patients at large United Kingdom Cancer Alliance including two tertiary referral hospitals and two district general hospital.

RESULTS:

A total of 276 cancer patients were included for analysis. Patients referred under the 2 weeks wait had were seen and diagnosed sooner from referral (p < 0.0001 and p < 0.0001 respectively). However, this did not translate into better survival outcomes. No survival differences were seen between those patients that were managed within the proposed cancer targets and those that were not.

CONCLUSIONS:

The 2 weeks wait head and neck cancer pathway did not offer a survival advantage. Targeting the delay in referral as well as delay in treatment to prevent late-stage cancer presentation is paramount. Fulfilment of cancer time targets do not translate into better outcomes and should not be prioritised to clinical judgement.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Cabeça e Pescoço Tipo de estudo: Observational_studies / Risk_factors_studies / Screening_studies Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Cabeça e Pescoço Tipo de estudo: Observational_studies / Risk_factors_studies / Screening_studies Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article